UB Paderborn / Katalog / Suche / in CDI

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients With Immunodeficiencies Receiving Weekly Immune Globulin Subcutaneous [Human] 20% Solution (Ig20Gly)

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB216

2020

Link zum Volltext

Verfügbarkeit prüfen

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin

Journal of clinical immunology, 2021-08, Vol.41 (6), p.1331-1338

2021

Link zum Volltext

Verfügbarkeit prüfen

Selective IgA Deficiency

Journal of clinical immunology, 2010, Vol.30 (1), p.10-16

Yel, Leman

2010

Link zum Volltext

Verfügbarkeit prüfen

Ig20Gly Tolerability and Infusion Characteristics in Pediatric and Advanced Age Patients With Primary Immunodeficiency Diseases

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB116-AB116

2019

Link zum Volltext

Verfügbarkeit prüfen

Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial

Journal of the peripheral nervous system, 2023-09, Vol.28 (3), p.436-449

2023

Link zum Volltext

Verfügbarkeit prüfen

Onboarding Experience of Pediatric Patients With Primary Immunodeficiency Diseases With Subcutaneous Human Immune Globulin 20% (Ig20Gly)

Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB268-AB268

2018

Link zum Volltext

Verfügbarkeit prüfen

Autoimmunity and Inflammation in X-linked Agammaglobulinemia

Journal of clinical immunology, 2014-08, Vol.34 (6), p.627-632

2014

Link zum Volltext

Verfügbarkeit prüfen

Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10

Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB26-AB26

2018

Link zum Volltext

Verfügbarkeit prüfen

Infusion Parameters and Adverse Events in Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin

Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB267-AB267

2018

Link zum Volltext

Verfügbarkeit prüfen

Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination

Nature immunology, 2003-10, Vol.4 (10), p.1023-1028

2003

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Immunological Features in IgM Deficiency

International archives of allergy and immunology, 2009-01, Vol.150 (3), p.291-298

2009

Link zum Volltext

Verfügbarkeit prüfen

Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability

Immunotherapy, 2016-10, Vol.8 (10), p.1175-1186

2016

Link zum Volltext

Verfügbarkeit prüfen

Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB117-AB117

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents

Immunotherapy, 2019-08, Vol.11 (12), p.1057-1065

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and Tolerability Of An Intravenously Administered Alpha1-Proteinase Inhibitor (A1PI) At An Increased Infusion Rate: A Randomized, Rate Control, Placebo-Masked, Crossover Study In Healthy Adults

Journal of allergy and clinical immunology, 2014-02, Vol.133 (2), p.AB181-AB181

2014

Link zum Volltext

Verfügbarkeit prüfen

Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials

BMC immunology, 2020-05, Vol.21 (1), p.24-24, Article 24

2020

Link zum Volltext

Verfügbarkeit prüfen

Improved Treatment Satisfaction with a New Human Subcutaneous Immunoglobulin (SCIG 20%) in Patients Previously Treated with IVIG

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB219-AB219

2017

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home

Journal of clinical immunology, 2006-01, Vol.26 (1), p.65-72

2006

Link zum Volltext

Verfügbarkeit prüfen

Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies

Immunotherapy, 2019-04, Vol.11 (5), p.397-406

2019

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB217-AB217

2017

Link zum Volltext

Verfügbarkeit prüfen

Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB216-AB216

2017

Link zum Volltext

Verfügbarkeit prüfen

A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB216-AB216

2017

Link zum Volltext

Verfügbarkeit prüfen

Arsenic Trioxide Induces Apoptosis in Peripheral Blood T Lymphocyte Subsets by Inducing Oxidative Stress: A Role of Bcl-2

Molecular cancer therapeutics, 2003-08, Vol.2 (8), p.711-719

2003

Link zum Volltext

Verfügbarkeit prüfen

Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB18-AB18

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB221-AB221

2016

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients With Immunodeficiencies Receiving Weekly Immune Globulin Subcutaneous [Human] 20% Solution (Ig20Gly)

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin

Selective IgA Deficiency

Ig20Gly Tolerability and Infusion Characteristics in Pediatric and Advanced Age Patients With Primary Immunodeficiency Diseases

Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial

Onboarding Experience of Pediatric Patients With Primary Immunodeficiency Diseases With Subcutaneous Human Immune Globulin 20% (Ig20Gly)

Autoimmunity and Inflammation in X-linked Agammaglobulinemia

Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10

Infusion Parameters and Adverse Events in Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin

Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination

Clinical and Immunological Features in IgM Deficiency

Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability

Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study

Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents

Safety and Tolerability Of An Intravenously Administered Alpha1-Proteinase Inhibitor (A1PI) At An Increased Infusion Rate: A Randomized, Rate Control, Placebo-Masked, Crossover Study In Healthy Adults

Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials

Improved Treatment Satisfaction with a New Human Subcutaneous Immunoglobulin (SCIG 20%) in Patients Previously Treated with IVIG

Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home

Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies

Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20

Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)

A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America

Arsenic Trioxide Induces Apoptosis in Peripheral Blood T Lymphocyte Subsets by Inducing Oxidative Stress: A Role of Bcl-2

Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies

Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America

Suchergebnisse filtern